Jastreboff AM, Ryan DH, Bays HE, Ebeling PR, Mackowski MG, Philipose N, Ross L, Liu Y, Burns CE, Abbasi SA, Pannacciulli N
The inherent pharmacokinetic limitations of native GLP-1, such as its short biological half-life, have catalyzed significant advancements through in-depth research into its physiology, secretion dynamics, and molecular characteristics
Unlike peptides requiring strict handling protocols, L-Carnitines small molecule structure and ionic nature confer enhanced stability for diverse experimental applications
Protein Cell 12(5):360373 Kessoku T, Imajo K, Kobayashi T, Ozaki A, Iwaki M, Honda Y et al (2020) Lubiprostone in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled, phase 2a trial
But studies are needed to prove whether GLP-1s improve RA symptoms and disease activity, says Karacabeyli
Inhibition of gap junction composed of Cx43 prevents against acute kidney injury following liver transplantation